AIDS Therapies (Ritonavir)

Monotherapy Demonstrates Potent Antiviral Effects

Published in AIDS Weekly, December 18th, 1995

Monotherapy with the experimental protease inhibitor ritonavir (formerly known as ABT-538) significantly reduced plasma viremia and elevated CD4 lymphocyte counts in HIV infected people, according to a new multi-center study published in the December 7, 1995, issue of the New England Journal of Medicine.

"Ritonavir monotherapy appears to be well-tolerated and is associated with potent antiviral effects and immunologic benefit in AIDS patients. Expanded clinical trials of ritonavir are needed," said Martin Markowitz, M.D., staff investigator at New York's Aaron Diamond AIDS Research Center and principal author of the article.

The study was a 12-week...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1995-12-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry